PMID- 21039786
OWN - NLM
STAT- MEDLINE
DCOM- 20110131
LR  - 20181201
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 37
IP  - 11
DP  - 2010 Nov
TI  - Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory 
      drug-induced urticaria and angioedema.
PG  - 973-9
LID - 10.1111/j.1346-8138.2010.00948.x [doi]
AB  - It has been proposed that aspirin (ASA) and other non-steroidal anti-inflammatory 
      drug (NSAID)-induced urticaria (UR)/angioedema (AE) are mediated through 
      inhibition of cyclooxygenase-1 (COX-1) enzymes. Therefore, drugs with COX-2 
      selectivity may be well tolerated in such patients. We investigated the safety of 
      preferential COX-2 inhibitor meloxicam in subjects with UR or AE type intolerance 
      reaction to classical ASA/NSAIDs. Subjects with reliable or documented history of 
      UR/AE due to classical ASA/NSAIDs underwent a single-blinded, placebo-controlled 
      oral challenge with a cumulative dose of 7.5 mg meloxicam on 2 separate days. 
      One-quarter and three-quarter divided doses of placebo and the active drug were 
      given at 1-h intervals. A total of 116 patients (86 women and 30 men, mean age 
      39.6 +/- 12.7 years) were enrolled to the study. The rate of atopy was 25.9%. Mean 
      duration of drug reaction was 87.4 +/- 110.8 (1-720) months. Almost half of the 
      patients were multi-reactors. The most comorbid disease was asthma and the two 
      most frequent NSAIDs inducing UR/AE were paracetamol (19. 6%) and ASA (19%). No 
      reaction to placebo was observed. Ten out of 116 patients (8.6%) developed mild 
      UR/AE, or only erythema and pruritus at a one-quarter or cumulative dose of 7.5 
      mg of meloxicam. The remaining subjects (91.4%) tolerated perfectly meloxicam 
      challenge. This study indicates that 7.5 mg meloxicam is a safe alternative for 
      ASA/NSAID-intolerant UR/AE patients. Intolerance reactions to meloxicam are much 
      milder forms of the patients' historical ASA/NSAID-induced cutaneous reactions.
CI  - (c) 2010 Japanese Dermatological Association.
FAU - Goksel, Ozlem
AU  - Goksel O
AD  - Department of Immunology and Allergy, Ankara University School of Medicine, 
      Ankara, Turkey.
FAU - Aydin, Omur
AU  - Aydin O
FAU - Misirligil, Zeynep
AU  - Misirligil Z
FAU - Demirel, Yavuz S
AU  - Demirel YS
FAU - Bavbek, Sevim
AU  - Bavbek S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20100816
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Thiazines)
RN  - 0 (Thiazoles)
RN  - R16CO5Y76E (Aspirin)
RN  - VG2QF83CGL (Meloxicam)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Angioedema/*chemically induced
MH  - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
MH  - Aspirin/*adverse effects
MH  - Cyclooxygenase 2 Inhibitors/*administration & dosage/adverse effects
MH  - Drug Hypersensitivity/diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Meloxicam
MH  - Middle Aged
MH  - Single-Blind Method
MH  - Skin Tests
MH  - Thiazines/*administration & dosage/adverse effects
MH  - Thiazoles/*administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Urticaria/*chemically induced
EDAT- 2010/11/03 06:00
MHDA- 2011/02/01 06:00
CRDT- 2010/11/03 06:00
PHST- 2010/11/03 06:00 [entrez]
PHST- 2010/11/03 06:00 [pubmed]
PHST- 2011/02/01 06:00 [medline]
AID - 10.1111/j.1346-8138.2010.00948.x [doi]
PST - ppublish
SO  - J Dermatol. 2010 Nov;37(11):973-9. doi: 10.1111/j.1346-8138.2010.00948.x. Epub 
      2010 Aug 16.